Cyclacel Pharmaceuticals, Inc.

384 articles with Cyclacel Pharmaceuticals, Inc.

• Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/10/2022

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced second quarter 2022 financial results and provided a business update.

• Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

  8/3/2022

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022.

• Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

  6/30/2022

  Cyclacel Pharmaceuticals, Inc. announced that it has achieved key business objectives in the first half of 2022 and provided a review of progress with its two clinical stage drug candidates.

• Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

  6/22/2022

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors.

• 

  How to Navigate a Career Change From Pharma to Biotech

  6/21/2022

  If you’re considering a career change from pharma to biotech, you’ll be happy to hear that according to industry experts, the transition is more common than you might think.
• 

  How to Navigate a Career Change From Biotech To Pharma 

  5/11/2022

  BioSpace spoke with industry experts to find out the differences between working in pharma and biotech and how to know if a pharma company is right for you.

• Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

  5/11/2022

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced first quarter 2022 financial results and provided a business update.

• Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

  5/4/2022

  Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on Wednesday, May 11, 2022.

• Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

  4/19/2022

  Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s streamlined, multi-cohort Phase 1/2 study of oral CYC140 in patients with advanced solid tumors and lymphomas.

• Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

  4/12/2022

  Cyclacel Pharmaceuticals, Inc. today announced a publication in the journal Leukemia.

• Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

  3/28/2022

  Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2021.

• Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

  3/22/2022

  Cyclacel Pharmaceuticals, Inc. will announce fourth quarter and full year 2021 financial results on Monday, March 28, 2022.

• Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

  3/9/2022

  Cyclacel Pharmaceuticals, Inc. today announced that management will be presenting at the virtual 32nd Annual Oppenheimer Healthcare Conference and participating in the Targeted Oncology Panel as part of the Conference.

• Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

  2/7/2022

  Cyclacel Pharmaceuticals, Inc. today announced that the Company will participate in the 2022 BIO CEO & Investor Conference on February 14-17, 2022.

• 

  From Zero to Hero: Biopharma's Pivotal Inflection Point

  1/27/2022

  Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
• 

  Outsmarting Cancer: Next Generation Therapies

  1/13/2022

  Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...

• Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

  1/6/2022

  Cyclacel Pharmaceuticals, Inc. today provided a business update reviewing 2021 achievements and outlining the Company’s key business objectives for 2022.

• Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

  12/23/2021

  Cyclacel Pharmaceuticals, Inc. today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022.

• Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021.

• Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

  11/5/2021

  Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS).